These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 16640105)

  • 1. A randomized, placebo-controlled trial of thymosin-alpha1 and lymphoblastoid interferon for HBeAg-positive chronic hepatitis B.
    Lim SG; Wai CT; Lee YM; Dan YY; Sutedja DS; Wee A; Suresh S; Wu YJ; Machin D; Lim CC; Fock KM; Koay E; Bowden S; Locarnini S; Ishaque SM
    Antivir Ther; 2006; 11(2):245-53. PubMed ID: 16640105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of thymosin α-1 plus peginterferon α-2a combination therapy compared with peginterferon α-2a monotherapy in HBeAg-positive chronic hepatitis B: a prospective, multicenter, randomized, open-label study.
    Kim BH; Lee YJ; Kim W; Yoon JH; Jung EU; Park SJ; Kim YJ; Lee HS
    Scand J Gastroenterol; 2012 Sep; 47(8-9):1048-55. PubMed ID: 22726105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study.
    You J; Zhuang L; Cheng HY; Yan SM; Yu L; Huang JH; Tang BZ; Huang ML; Ma YL; Chongsuvivatwong V; Sriplung H; Geater A; Qiao YW; Wu RX
    World J Gastroenterol; 2006 Nov; 12(41):6715-21. PubMed ID: 17075991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcomes of thymosin-alpha 1 and interferon alpha-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B.
    Saruc M; Ozden N; Turkel N; Ayhan S; Hock LM; Tuzcuoglu I; Yuceyar H
    J Pharm Sci; 2003 Jul; 92(7):1386-95. PubMed ID: 12820143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment with interferon and thymosin alpha-1 versus interferon monotherapy for HBeAg positive chronic hepatitis B: a meta-analysis].
    Mao HY; Shi TD
    Zhonghua Gan Zang Bing Za Zhi; 2011 Jan; 19(1):29-33. PubMed ID: 21272455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of chronic hepatitis B: case selection and duration of therapy.
    Leung N
    J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized controlled trial of thymosin-alpha1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody--and hepatitis B virus DNA--positive chronic hepatitis B.
    Andreone P; Cursaro C; Gramenzi A; Zavagliz C; Rezakovic I; Altomare E; Severini R; Franzone JS; Albano O; Ideo G; Bernardi M; Gasbarrini G
    Hepatology; 1996 Oct; 24(4):774-7. PubMed ID: 8855175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination thymosin-alpha 1 and interferon-alpha 2b in the treatment of anti-HBe-positive chronic hepatitis B in Turkey.
    Saruc M; Yuceyar H; Kucukmetin N; Demir MA; Kandiloglu AR
    Hepatogastroenterology; 2002; 49(45):798-802. PubMed ID: 12063993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
    Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
    Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
    Lau GK; Piratvisuth T; Luo KX; Marcellin P; Thongsawat S; Cooksley G; Gane E; Fried MW; Chow WC; Paik SW; Chang WY; Berg T; Flisiak R; McCloud P; Pluck N;
    N Engl J Med; 2005 Jun; 352(26):2682-95. PubMed ID: 15987917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: a meta-analysis.
    Yang YF; Zhao W; Zhong YD; Yang YJ; Shen L; Zhang N; Huang P
    Antiviral Res; 2008 Feb; 77(2):136-41. PubMed ID: 18078676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.
    Huang Z; Deng H; Zhao Q; Zheng Y; Peng L; Lin C; Zhao Z; Gao Z
    Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1165-9. PubMed ID: 23571612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.
    Piccolo P; Lenci I; Demelia L; Bandiera F; Piras MR; Antonucci G; Nosotti L; Mari T; De Santis A; Ponti ML; Sorbello O; Iacomi F; Angelico M
    Antivir Ther; 2009; 14(8):1165-74. PubMed ID: 20032546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
    Yue W; Yuan H; Mao XR; Deng YD; Chen L
    Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):184-8. PubMed ID: 23967738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy of thymosin alpha-1 and lamivudine for HBeAg positive chronic hepatitis B: A prospective randomized, comparative pilot study.
    Lee HW; Lee JI; Um SH; Ahn SH; Chang HY; Park YK; Hong SP; Moon YM; Han KH
    J Gastroenterol Hepatol; 2008 May; 23(5):729-35. PubMed ID: 18410608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
    Zheng MH; Shi KQ; Dai ZJ; Ye C; Chen YP
    Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine.
    van Zonneveld M; Zondervan PE; Cakaloglu Y; Simon C; Akarca US; So TM; Flink HJ; de Man RA; Schalm SW; Janssen HL;
    Liver Int; 2006 May; 26(4):399-405. PubMed ID: 16629642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.
    Perrillo RP; Lai CL; Liaw YF; Dienstag JL; Schiff ER; Schalm SW; Heathcote EJ; Brown NA; Atkins M; Woessner M; Gardner SD
    Hepatology; 2002 Jul; 36(1):186-94. PubMed ID: 12085364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.
    Janssen HL; van Zonneveld M; Senturk H; Zeuzem S; Akarca US; Cakaloglu Y; Simon C; So TM; Gerken G; de Man RA; Niesters HG; Zondervan P; Hansen B; Schalm SW; ;
    Lancet; 2005 Jan 8-14; 365(9454):123-9. PubMed ID: 15639293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial.
    Schalm SW; Heathcote J; Cianciara J; Farrell G; Sherman M; Willems B; Dhillon A; Moorat A; Barber J; Gray DF
    Gut; 2000 Apr; 46(4):562-8. PubMed ID: 10716688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.